[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371362-105":59,"doc-detail-371362-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","leveraging-glycosylation-for-early-detection-and-therapeutic-target-discovery-in-pancreatic-cancer","Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer","","Pancreatic cancer remains highly lethal, largely driven by late-stage diagnosis, limited biomarker sensitivity and specificity, and aggressive metastatic behavior. Glycoproteomic research highlights that glycosylation remodeling influences cell adhesion, immune evasion, and tumor invasiveness. Clinical markers such as CA19-9 are standard but inadequate for early disease, prompting investigation of additional candidates including mesothelin, THBS2, and specific glycan alterations. Therapeutic approaches that target glycosylation pathways and advanced translational models aim to validate diagnostic and treatment potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/leveraging-glycosylation-for-early-detection-and-therapeutic-target-discovery-in-pancreatic-cancer/371362/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/leveraging-glycosylation-for-early-detection-and-therapeutic-target-discovery-in-pancreatic-cancer/371362.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are glycosylation-related biomarkers important for pancreatic cancer early detection?","Question",{"text":112,"@type":113},"Glycosylation changes can influence cancer progression and may provide diagnostic signals beyond CA19-9, whose sensitivity and specificity are limited in early-stage disease. Glycoproteomic studies support combining or profiling biomarkers such as CA19-9 with additional glycosylation-linked markers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What biological processes related to glycosylation contribute to pancreatic cancer metastasis and immune evasion?",{"text":117,"@type":113},"Altered sialylation and fucosylation are associated with enhanced tumor cell adhesion and migration, as well as immune escape. These mechanisms highlight glycosylation as a potential therapeutic leverage point to limit metastasis.",{"name":119,"@type":110,"acceptedAnswer":120},"How can therapeutic strategies target glycosylation in pancreatic cancer?",{"text":121,"@type":113},"Therapies can aim to inhibit specific glycosylation pathways, including pathways connected to sialylation and fucosylation, to curb metastasis and improve immune responses. Translational platforms such as patient-derived xenografts and advanced in vitro models help assess therapeutic impact.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371362,1790493549,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","[www.nature.com/cddis](www.nature.com/cddis)  \nREVIEW ARTICLE OPEN   \nLeveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer  \nTomasz Pienkowski 1,2,5, Katarzyna Wawrzak-Pienkowska3,4,5, Anna Tankiewicz-Kwedlo2, Michal Ciborowski1, Krzysztof Kurek3 and Dariusz Pawlak 2 ✉  \n© The Author(s) 2025  \n\n|  | Pancreatic cancer (PC) remains one of the most lethal malignancies, primarily due to late-stage diagnosis, limited biomarkerspeciﬁcity, and aggressive metastatic potential. Recent glycoproteomic studies have illuminated the crucial role of glycosylation in PC progression, revealing altered glycosylation patterns that impact cell adhesion, immune evasion, and tumor invasiveness. Biomarkers such as CA19-9 remain the clinical standard, yet limitations in sensitivity and speciﬁcity, especially in early disease stages, necessitate the exploration of alternative markers. Emerging glycoproteins—such as mesothelin, thrombospondin-2, and glycan modiﬁcations like sialyl-Lewis x—offer diagnostic promise when combined with CA19-9 or used in proﬁling panels. Furthermore, therapeutic strategies targeting glycosylation processes, including sialylation, and fucosylation, have shown potential in curbing PC metastasis and enhancing immune response. Translational platforms, such as patient-derived xenografts and advanced in vitro models, are pivotal in validating these ﬁndings and assessing glycosylation potential therapeutic impact. Continued exploration of glycosylation-driven mechanisms and biomarker discovery in PC can signiﬁcantly advance early detection |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| and treatment efﬁcacy, offering new hope in the management of this challenging disease. |  |  |\n|  | Cell Death and Disease (2025)16:227; [https://doi.org/10.1038/s41419-025-07517-z](https://doi.org/10.1038/s41419-025-07517-z) |  |\n|  |  |  |\n\nFACTS  \n● Glycosylation-related biomarkers: biomarkers such as CA19-9, MSLN, and THBS2 offer diagnostic potential, with studies aiming to improve early detection accuracy through combinations with N-glycan proﬁles.  \n● Glycosylation-driven metastasis and immune evasion: alterations in sialylation and fucosylation enhance PC cell adhesion, migration, and immune escape, highlighting therapeutic targets for limiting metastasis.  \n● Therapeutic targeting of glycosylation pathways: inhibitors targeting speciﬁc glycosylation pathways (e.g., N-glycosylationin ferroptosis resistance) and the use of translational platforms hold promise for novel therapeutic strategies in PC treatment.  \nOPEN QUESTIONS  \n● How can glycoproteomic proﬁling be standardized across diverse patient cohorts to develop universally applicable biomarkers for early pancreatic cancer detection?  \n● What are the most effective strategies for therapeutically targeting aberrant glycosylation patterns in pancreatic cancer without disrupting normal glycosylation-dependent cellular functions?  \n● How does the dynamic regulation of glycosylation patterns contribute to pancreatic cancer progression, and can it be leveraged to monitor treatment response in real-time?  \nINTRODUCTION  \nPancreatic cancer is one of the leading causes of cancer-related fatalities, characterized by a poor prognosis. Approximately 90% of pancreatic tumors are classiﬁed as pancreatic ductal adenocarcinoma (PDAC), which has one of the lowest survival rates among all cancers. The median survival for patients diagnosed with pancreatic cancer is around six months, and the ﬁve-year survival rate is ~12%  \n[1]. One of the most signiﬁcant challenges in managing pancreatic cancer lies in its late presentation and the absence of accurate, reliable biomarkers for early detection [Table 1]. Patients frequently exhibit few, if any, noticeable symptoms, which often results in metastases being present at the time of diagnosis. It is estimated that 50–60% of pati","cbCaiih8Qf8NlW5j","https://ap.wps.com/l/cbCaiih8Qf8NlW5j","pdf",1291477,13,"English","# Introduction\n## Glycosylation and pancreatic cancer progression\n## Glycosylation-related biomarkers and diagnostic potential\n## Therapeutic targeting of glycosylation pathways\n## Translational validation platforms and open questions","[{\"question\":\"Why are glycosylation-related biomarkers important for pancreatic cancer early detection?\",\"answer\":\"Glycosylation changes can influence cancer progression and may provide diagnostic signals beyond CA19-9, whose sensitivity and specificity are limited in early-stage disease. Glycoproteomic studies support combining or profiling biomarkers such as CA19-9 with additional glycosylation-linked markers.\"},{\"question\":\"What biological processes related to glycosylation contribute to pancreatic cancer metastasis and immune evasion?\",\"answer\":\"Altered sialylation and fucosylation are associated with enhanced tumor cell adhesion and migration, as well as immune escape. These mechanisms highlight glycosylation as a potential therapeutic leverage point to limit metastasis.\"},{\"question\":\"How can therapeutic strategies target glycosylation in pancreatic cancer?\",\"answer\":\"Therapies can aim to inhibit specific glycosylation pathways, including pathways connected to sialylation and fucosylation, to curb metastasis and improve immune responses. Translational platforms such as patient-derived xenografts and advanced in vitro models help assess therapeutic impact.\"}]","Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer | PDF",1790191895,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05f6edbab09969106f2b6fb97fa2d642.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d0e2c9d41694b257cce49ebb5c74ea9.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42494acf9923021976a95e7b26c42fc7.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d817983b78221fdda31ee534e224fa97.webp",980,1301]